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Abstract: Acute myocardial infarction (AMI) is generally attributed to coronary atherothrombotic 
disease. Platelet activation is essential for thrombus formation and is thus an important target 
for pharmacological intervention to prevent and treat AMI. Despite contemporary treatment 
with dual antiplatelet therapy, including acetylsalicylic acid and adenosine diphosphate recep-
tor antagonists, patients with prior AMI remain at increased risk of future thrombotic events. 
This has stimulated the search for more potent antithrombotic agents. Among these is the oral 
protease-activated receptor-1 antagonist vorapaxar, which represents a new oral antiplatelet 
agent to reduce thrombotic risk in patients with atherothrombotic disease. The TRACER and 
the TRA 2°P-TIMI 50 trials concluded that vorapaxar in addition to standard therapy reduced 
ischemic adverse cardiac events. A remarkable benefit was observed in patients with stable 
atherosclerotic disease, particularly those with a previous history of AMI. Although favorable 
effects were seen in reduction of adverse cardiac events, this was associated with excess major 
and intracranial bleeding, particularly in patients at high risk of bleeding and those with a his-
tory of stroke or transient ischemic attack. Currently, the lack of a reliable individualized risk 
stratification tool to assess patients for thrombotic and bleeding tendencies in order to identify 
those who might gain most net clinical benefit has led to limited use of vorapaxar in clinical 
practice. Vorapaxar may find a niche as an adjunct to standard care in patients at high risk of 
thrombotic events and who are at low risk of bleeding.
Keywords: myocardial infarction, thrombosis, antiplatelet agents, protease-activated receptor-1, 
vorapaxar
Introduction
The predominant cause of death from cardiovascular disease is believed to be coronary 
artery thrombosis.1–3 Thrombotic occlusion of a coronary artery in response to athero-
sclerotic plaque rupture is considered the ultimate and key step in the pathogenesis of 
acute myocardial infarction (AMI).4 The propensity to provoke thrombosis depends on 
a complex cascade of events involving inflammatory pathways, and more importantly, 
platelet activation with subsequent aggregation.5 Guidelines recommend dual antiplatelet 
therapy with acetylsalicylic acid and adenosine diphosphate (ADP) receptor antagonists 
for a period of up to 1 year following the qualifying AMI event, to reduce recurrent 
thrombosis.6–9 The introduction of more potent oral antiplatelet agents, such as the 
more recent ADP receptor antagonists ticagrelor and prasugrel, has further reduced the 
risk of recurrent thrombosis.10,11 However, despite modern treatments, many patients 
remain at increased risk of future thrombotic events. In recent studies, some 10%–15% 
of patients went on to have a major adverse cardiac event during the first 12 months 
after AMI, which was attributed predominantly to thrombotic complications.12–15 
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Additionally, there has been a growing concern over the 
safety profile of oral antiplatelet agents in terms of increased 
bleeding, which is now known to be a marker of an adverse 
prognosis and has negatively affected their use.10,16 In order to 
reduce thrombotic risk even further, oral anticoagulant agents 
were added to dual antiplatelet therapy, but this was found 
to be associated with increased bleeding.17,18 This has led to 
the search for novel antiplatelet agents with effects to reduce 
thrombotic risk, taking into consideration the potential for 
excess bleeding. Among these are the oral protease-activated 
receptor (PAR)-1 antagonists, which represent a new class 
of oral antiplatelet agents for patients with atherothrombotic 
disease. A key step in the process of thrombus formation is the 
role thrombin plays in the activation of platelets by binding to 
PARs, especially PAR-1.19 Targeting this thrombin signaling 
receptor has led to greater inhibition of platelet activation and 
inhibition, and in turn of thrombosis.
Several PAR-1 antagonists have been evaluated for clini-
cal use. The clinical efficacy appeared to be superior with 
vorapaxar, compared with atopaxar, but this was associated 
with a higher risk of serious bleeding.20 Only vorapaxar has 
completed Phase III clinical trial investigation to assess 
its efficacy and safety in the clinical arena.21,22 The present 
review provides an overview of the role of adjunctive therapy 
with vorapaxar in the secondary prevention of atherothrom-
botic disease, particularly AMI, and the potential role for 
vorapaxar in modern practice.
Mechanism of action of PAR-1 
antagonism with vorapaxar
Hemostasis is considered a protective mechanism that 
maintains the integrity of blood vessels after vascular injury. 
Thrombin signaling in platelets contributes to hemostasis and 
thrombosis by converting circulating fibrinogen into fibrin, the 
fibrous matrix of blood clots. The cellular effects of thrombin 
are mainly mediated by PARs.23 The mechanism of PAR acti-
vation and signaling is complex. PARs are G protein-coupled 
receptors that are expressed in vascular endothelial cells and 
activated by cleavage of part of their extracellular domain, 
causing the physiological response.24 They play an important 
role in thrombosis, coagulation, hemostasis, atherosclerosis, 
and inflammation.25–27 There are four known types of PARs, 
numbered from PAR-1 to PAR-4. Thrombin triggers platelet 
activation with subsequent aggregation primarily by activat-
ing PAR-1 and PAR-4. PAR-1 is activated at a much smaller 
concentration, resulting in rapid platelet activation.28 Many 
of the downstream mediators of the PAR-1 pathway, such as 
thromboxane A
2
 and ADP, are involved in platelet activation. 
In an animal model, administration of the PAR-1 antagonist 
vorapaxar caused complete and dose-dependent inhibition 
of thrombin receptor activating peptide (TRAP)-induced 
platelet aggregation without affecting the coagulation cascade, 
including activated clotting time, prothrombin time, and acti-
vated partial thromboplastin time, a finding that is consistent 
with the fact that this agent interacts with specific platelet 
receptors,29 and suggested that it could inhibit thrombosis 
without undue bleeding risk.
Vorapaxar (formerly known as SCH 530348) is a syn-
thetic tricyclic 3-phenylpyridine derived from the natural 
product himbacine. It is an oral competitive PAR-1 antagonist 
that exerts its action by inhibition of TRAP-induced platelet 
aggregation in a dose-dependent manner30 (Figure 1). The 
loading dose is 20 or 40 mg, with a higher dose achieving 
greater inhibition of platelet aggregation, and the mainte-
nance dose is 2.5 mg daily.31 Vorapaxar is rapidly absorbed 
via the gastrointestinal tract, with high bioavailability. Its 
peak concentration is 1–2 hours after oral loading and it has 
a half-life of 159–310 hours, with no antidote available at 
present.32 Vorapaxar is predominantly metabolized via the 
cytochrome P450 3A4 pathway and is mainly excreted in 
bile with only minor renal excretion.32,33
A summary of key randomized trials evaluating the use 
of vorapaxar in the three phases of clinical trial investigation 
is shown in Table 1.
Phase I clinical trial data
In healthy Caucasian subjects, single 20 and 40 mg doses 
of vorapaxar administered in a randomized, double-blind 
placebo-controlled fashion inhibited TRAP-induced platelet 
aggregation (.80% inhibition) at 1 hour, and this level of 
inhibition was sustained for up to 72 hours.34 Multiple ascend-
ing doses for 28 days (1, 3, or 5 mg/day) resulted in complete 
inhibition of platelet aggregation on day 1 (5 mg/day) and 
day 7 (1 and 3 mg/day). Adverse events were generally mild 
and unrelated to dose. In another randomized open-label 
trial in healthy Japanese and matched Caucasian subjects, 
complete inhibition of TRAP-induced platelet aggregation 
was achieved most rapidly with vorapaxar 40 mg and was 
sustained with a maintenance dose of 2.5 mg daily.35 No 
racial difference as regard to the safety, pharmacokinetics, 
or pharmacodynamics of vorapaxar was found. These find-
ings supported further investigation of vorapaxar in Phase 
II clinical trials.
Phase II clinical trial data
TRA-PCI (Thrombin Receptor Antagonist Percutane-
ous Coronary Intervention) was a multicenter, random-
ized, double-blind, placebo-controlled trial of patients 
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Role of vorapaxar in myocardial infarction
Figure 1 Targets of antithrombotic and antiplatelet agents including vorapaxar (SCH 530348). 
Note: Reproduced with permission from Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis, Eur Heart J. 2010;31(1):17–28. 
By permission of Oxford University Press.19
Abbreviations: ADP, adenosine diphosphate; COX, cyclo-oxygenase; vwF, von willebrand factor; PAR, protease-activated receptor; TxA2, thromboxane A2.
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undergoing non-urgent or elective percutaneous coronary 
intervention (PCI).31 This was a Phase II trial involving 
1,030 patients comparing different oral loading doses of 10, 
20, and 40 mg vorapaxar followed by maintenance doses 
of 0.5, 1, and 2 mg daily against matched placebo in a 3:1 
ratio. After the loading doses, the vorapaxar group contin-
ued receiving vorapaxar maintenance doses and the placebo 
group continued placebo for 60 days after PCI. Patients 
were continued on standard dual antiplatelet therapy with 
acetylsalicylic acid and ADP receptor antagonists during 
the study. The primary endpoint was the incidence of TIMI 
(Thrombolysis In Myocardial Infarction) major bleeding 
(defined as intracranial hemorrhage, overt bleeding associ-
ated with a fall in hemoglobin .5 g/dL), or TIMI minor 
bleeding (defined as overt clinical signs of bleeding associ-
ated with a hemoglobin reduction of 3–5 g/dL) in the PCI 
cohort. The secondary endpoints were overt bleeding that 
did not meet TIMI criteria (defined as clinically overt signs 
of bleeding with a reduction in hemoglobin ,3 g/dL), or 
ischemic events (defined as composite of death, myocardial 
infarction [MI], and stroke). The study showed no increased 
risk of TIMI major or minor bleeding or non-TIMI bleeding 
with vorapaxar using any of the dosing regimens compared 
with placebo. As the study was underpowered, there was a 
non-significant reduction in ischemic events among PCI-
treated patients with vorapaxar using any of the dosing 
regimens compared with placebo (odds ratio 0.67; 95% 
confidence interval [CI] 0.33–1.34). The conclusion of 
the TRA-PCI study was that, in addition to standard dual 
antiplatelet therapy, vorapaxar was well tolerated and not 
associated with an increased risk of bleeding compared with 
placebo in patients undergoing PCI.
Another Phase II trial was reported by Goto et al.36 This 
was a multicenter, randomized, double-blind, placebo-
controlled trial performed to assess the efficacy and safety of 
vorapaxar in Japanese patients with non-ST-segment eleva-
tion MI planned for PCI. The study involved 117 patients 
to compare two different vorapaxar oral loading doses of 
20 mg and 40 mg followed by maintenance doses of 1 mg 
and 2.5 mg daily against matched placebo in a 4:1 ratio. 
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Role of vorapaxar in myocardial infarction
The patients received loading doses of standard-of-care 
medication at the time of the study (acetylsalicylic acid, 
ticlopidine, and heparin) as well as a loading dose of the 
study treatment; the vorapaxar group continued receiving 
vorapaxar maintenance doses and the placebo group contin-
ued placebo for 60 days after PCI. Patients were continued 
on standard dual antiplatelet therapy with acetylsalicylic acid 
and ADP receptor antagonists during the study. The efficacy 
endpoint was major adverse cardiac event or all-cause death 
and the safety endpoint was TIMI major and minor bleed-
ing or non-TIMI bleeding. The study showed a significant 
reduction in peri-procedural AMI in the group treated with 
vorapaxar compared with the placebo group (16.9% versus 
42.9%, respectively; P=0.013). Peri-procedural AMI was 
defined as elevation of cardiac enzymes above three times 
the upper limit of normal, with at least a 50% increase from 
the value prior to the procedure. The incidence of combined 
TIMI major and minor bleeding was 14% in the vorapaxar 
group and 10% in the placebo group. TIMI major bleeding 
occurred in five patients (7%) in the vorapaxar group versus 
none in the placebo group. The rates of non-TIMI bleeding or 
bleeding of any severity were comparable between the two 
groups. The authors concluded that in addition to standard 
dual antiplatelet therapy, vorapaxar significantly reduced the 
incidence of peri-procedural MI in Japanese patients under-
going urgent PCI without resulting in excess bleeding.
Phase III clinical trial data
To date, two large randomized clinical trials have been 
conducted, ie, TRACER (Thrombin Receptor Antagonist 
for Clinical Event Reduction in Acute Coronary Syndrome) 
and TRA 2°P-TIMI 50 (Thrombin Receptor Antagonist 
in Secondary Prevention of Atherothrombotic Ischemic 
Events-Thrombolysis in Myocardial Infarction 50).21,22 
Several hypothesis-generating subgroup analyses were 
derived from these trials. In this review, we highlight the 
key findings and important data from these trials.
TRACeR
TRACER was the first large study to evaluate the efficacy 
and safety of vorapaxar.21 It was a multicenter, random-
ized, double-blind, placebo-controlled, Phase III trial, in 
which patients with non-ST-segment elevation MI (12,944 
patients) received vorapaxar at a loading dose of 40 mg and 
a daily maintenance dose of 2.5 mg thereafter, or matched 
placebo. Management of the patients included medical therapy 
(32.2%), PCI (57.7%), and coronary artery bypass grafting 
(CABG, 10.1%), according to usual clinical care. Patients 
were continued on standard dual antiplatelet therapy with 
acetylsalicylic acid and an ADP receptor antagonist during 
the study. The primary efficacy endpoint was a composite 
of cardiovascular death, MI, stroke, recurrent ischemia with 
rehospitalization, and urgent coronary revascularization. 
The primary safety endpoints were a composite of moderate 
or severe bleeding according to the GUSTO (Global Use of 
Strategies to Open Occluded Coronary Arteries) classification 
and clinically significant bleeding according to the TIMI clas-
sification. The trial was terminated early owing to safety con-
cerns. At a median follow-up of 502 days, the study primary 
composite ischemic endpoint was non-significantly reduced 
in patients randomized to vorapaxar when compared with 
placebo (18.5% versus 19.9%; hazard ratio [HR] 0.92; 95% CI 
0.85–1.01; P=0.07). However, a secondary non-prespecified 
ischemic endpoint (defined as composite of cardiovascular 
death, MI, or stroke) was significantly reduced with vorapaxar 
(14.7% versus 16.4%; HR 0.89; 95% CI 0.81–0.98; P=0.02). 
The rate of moderate or severe bleeding (GUSTO classifica-
tion) was higher with vorapaxar compared with placebo (7.2% 
versus 5.2%; HR 1.35; 95% CI 1.16–1.58; P,0.001). Also, 
the rate of intracranial hemorrhage was higher with vorapaxar 
(1.1% versus 0.2%; HR 3.39; 95% CI 1.78–6.45; P,0.001) 
compared with placebo. The data and safety monitoring board 
recommended premature termination of the trial as a result of 
increased bleeding risk with vorapaxar. The conclusion of the 
study was that in addition to standard dual antiplatelet therapy, 
although vorapaxar partially reduced ischemic events, its 
use significantly increased bleeding, including major and 
intracranial bleeding.
Subgroup analyses play an important role in the inter-
pretation of clinical trials. The net clinical benefit, defined 
as the difference in ischemic and bleeding event rates, was 
evaluated in a post hoc analysis of the TRACER trial.37 
The analysis was performed by application of multivari-
ate risk stratification strategies, which were unique to this 
analysis and not widely validated. The results showed that 
vorapaxar was associated with an improved net benefit in a 
large group of patients with acute coronary syndrome (ACS) 
at high risk of recurrent ischemic events and at low risk of 
bleeding (26% of patients; net benefit +2.8%). However, 
among patients with a high risk of bleeding and irrespective 
of ischemic risk (low or high), vorapaxar was associated 
with worse net benefit (11% of patients; net benefit -3%). 
Vorapaxar exerted a neutral effect on those with a low risk of 
bleeding and a low risk of ischemic events (63% of patients; 
net benefit -0.1%). The results of this analysis highlight the 
potentially beneficial role of vorapaxar in patients at high risk 
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of ischemic events and low risk of bleeding, but similarly, 
the potential for harm using vorapaxar in patients at high 
risk of bleeding.
Although the TRACER trial did not meet its primary 
efficacy endpoint, a significant reduction in the rate of MI was 
observed with vorapaxar compared with placebo. Therefore, 
the effect of vorapaxar on MI was further explored in a post 
hoc analysis.38 A blinded, independent central endpoint 
adjudication committee prospectively defined and classified 
MI according to the universal MI definition.39 During a 
median follow-up of 502 days, 1,580 MI events occurred in 
1,319 patients. Compared with placebo, vorapaxar reduced 
the hazard of a first MI of any type by 12% (HR 0.88; 95% 
CI 0.79–0.98; P=0.021) and the hazard of total numbers 
of MI (first and subsequent) by 14% (HR 0.86; 95% CI 
0.77–0.97; P=0.014). Also, vorapaxar reduced type 1 MI (the 
most common type) by 17% (HR 0.83; 95% CI 0.73–0.95; 
P=0.007), but not type 4a MI (PCI-related, HR 0.90; 95% CI 
0.73–1.12; P=0.35) compared with placebo. These findings 
support the potential role of vorapaxar in the management 
of ACS patients at high-risk of future MI events.
Platelet activation and thrombosis play an important role 
in acute bypass graft occlusion. A post hoc analysis was 
performed for the subgroup of 1,312 patients who under-
went CABG in the TRACER trial.40 Of these, 78% were on 
vorapaxar at the time of surgery. Compared with placebo, the 
vorapaxar group had a 45% significant reduction in incidence 
of the primary composite ischemic endpoint, ie, a composite 
of cardiovascular death, MI, stroke, recurrent ischemia with 
rehospitalization, and urgent coronary revascularization (HR 
0.55; 95% CI 0.36–0.83; P=0.005). These findings differed 
significantly from the non-CABG group, with a significant 
interaction (P=0.012). CABG-related major bleeding was 
similar with vorapaxar and placebo (9.7% versus 7.3%; HR 
1.36; 95% CI 0.92–2.02; P=0.12). Although derived from 
subgroup analysis, these results show promise for use of 
vorapaxar in ACS patients undergoing CABG.
Another post hoc analysis was performed according to 
stent type in the 7,479 patients who underwent PCI in the 
TRACER trial (n=7,479).41 The efficacy and safety of vora-
paxar among PCI patients were largely consistent with the 
overall TRACER trial results. A trend toward reduction in 
ischemic events and less bleeding was noted in patients who 
had bare metal stents compared with drug-eluting stents. In 
another post hoc analysis of ACS patients who were initially 
managed with medical treatment (n=4,194), the efficacy and 
safety of vorapaxar appeared consistent with the overall 
TRACER trial results.42
TRA 2°P-TiMi 50
TRA 2°P-TIMI 50 was a secondary prevention study.22 
This was a multicenter, randomized, double-blind, placebo-
controlled, Phase III trial. Patients with a history of MI, isch-
emic stroke, or peripheral arterial disease (26,449 patients) 
received vorapaxar (2.5 mg daily) or matching placebo. 
Patients were continued on standard-of-care therapy with 
acetylsalicylic acid or ADP receptor antagonists during 
the study. The study excluded patients with a high risk of 
bleeding, including those who had a history of bleeding 
diathesis or recent active bleeding, were receiving concur-
rent anticoagulation therapy, or had active hepatobiliary 
disease. The primary efficacy endpoint was the composite 
of cardiovascular death, MI, or stroke. The primary safety 
endpoints were a composite of moderate or severe bleeding 
according to the GUSTO classification and clinically sig-
nificant bleeding according to the TIMI classification. The 
composite of cardiovascular death, MI, stroke, or recurrent 
ischemia leading to urgent coronary revascularization was the 
major secondary efficacy endpoint. The trial was terminated 
early owing to safety concerns. At a median follow-up of 
30 months, the primary efficacy endpoint occurred in 9.3% of 
the vorapaxar group and in 10.5% of the placebo group (HR 
0.87; 95% CI 0.80–0.94; P,0.001). The secondary efficacy 
endpoint occurred in 11.2% of the vorapaxar group and in 
12.4% of the placebo group (HR 0.88; 95% CI 0.82–0.95; 
P=0.001). The ischemic benefit observed with vorapaxar was 
driven mainly by a reduction in MI (5.2% versus 6.1%; HR 
0.83; 95% CI 0.74–0.93; P=0.001). Also, the incidence of 
cardiovascular death or MI was less with vorapaxar (7.3% 
versus 8.2%; P=0.002). No treatment difference was found 
in the incidence of stroke or death from any cause. The rate 
of moderate or severe bleeding (GUSTO classification) was 
higher with vorapaxar than with placebo (4.2% versus 2.5%; 
HR 1.66; 95% CI 1.43–1.93; P=0.001). The rate of intrac-
ranial hemorrhage was also notably higher with vorapaxar 
(1.0% versus 0.5%; HR 1.94; 95% CI 1.39–2.70; P,0.001). 
The data and safety monitoring board recommended prema-
ture termination of the trial in patients with a history of stroke 
or new stroke as a result of an increased risk of intracranial 
hemorrhage with vorapaxar. The conclusion of the study was 
that vorapaxar in addition to standard therapy reduced the risk 
of composite cardiovascular death, MI, and stroke, with the 
most benefit observed in patients with a stable atherosclerotic 
disease, particularly those with a previous history of MI. 
However, this resulted in a significant increase in bleeding 
risk, particularly intracranial hemorrhage in patients with a 
history of stroke.
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Role of vorapaxar in myocardial infarction
In a subgroup analysis of patients with a history of 
ischemic stroke (n=4,883),43 vorapaxar increased the risk 
of intracranial hemorrhage compared with placebo (2.5% 
versus 1.0%; HR 2.52; 95% CI 1.46–4.36; P,0.001). 
Also, vorapaxar increased the risk of moderate and severe 
bleeding (4.2% versus 2.4%; HR 1.93; 95% CI 1.33–2.79; 
P,0.001), without any significant effect on the primary 
ischemic endpoint (13.0% versus 11.7%; P=0.75). This analy-
sis highlighted the potential harm of vorapaxar in patients 
with a history of stroke.
Another large subgroup analysis was performed of patients 
with a prior MI within the previous 2 weeks to 12 months 
(17,779 patients).44 Vorapaxar significantly reduced the 
primary ischemic endpoint compared with placebo (8.1% 
versus 9.7%; HR 0.80; 95% CI 0.72–0.89; P,0.0001). 
This benefit was consistent in all key subgroups, including 
subgroup analysis based on timing between the qualifying 
MI events and randomization; ,3 months (HR 0.82; 95% 
CI 0.70–0.95; P=0.011), 3–6 months (HR 0.79; 95% CI 
0.65–0.97; P=0.023), and .6 months (HR 0.78; 95% CI 
0.62–0.97; P=0.026). However, the observed benefit occurred 
at a cost of an excess of moderate or severe bleeding (vora-
paxar group 3.4% versus placebo group 2.1%; HR 1.61; 95% 
CI 1.31–1.97; P,0.0001), and clinically significant bleed-
ing (vorapaxar group 15.1% versus placebo group 10.4%; 
HR 1.49; 95% CI 1.36–1.63; P,0.0001). In this subgroup 
analysis, there was no significant risk of intracranial hem-
orrhage associated with vorapaxar compared with placebo 
(0.6% versus 0.4%; HR 1.54; 95% CI 0.96–2.48; P=0.076). 
In a further analysis of patients at low bleeding risk, defined 
as those ,75 years of age and without a history of stroke or 
transient ischemic attack, similar results were obtained, with 
still significantly higher rates of moderate or severe bleed-
ing with vorapaxar than with placebo (2.7% versus 1.8%), 
although with fewer bleeds overall. The conclusion of this 
analysis was that prolonged treatment with vorapaxar when 
added to standard antiplatelet therapy may be beneficial for 
long-term secondary prevention in patients with prior MI.
The efficacy of vorapaxar in terms of the occurrence of 
stent thrombosis (defined using Academic Research Con-
sortium criteria), was recently investigated.45,46 During a 
median follow-up of 30 months, there were 152 definite stent 
thrombosis events, with the majority (92%) occurring late 
(30 days to 1 year) or very late (.1 year). Vorapaxar con-
sistently reduced stent thrombosis including very late stent 
thrombosis (1.1% versus 1.4%; HR 0.71; 95% CI 0.51–0.98; 
P=0.037), regardless of dual antiplatelet use, stent type, his-
tory of diabetes, or time from PCI.
Conclusion
Patients with atherosclerosis and those with prior thrombotic 
events such as MI are at increased risk of future thrombotic 
events. Since platelet activation is an essential key step in 
thrombus formation, aggressive secondary preventive mea-
sures with antiplatelet agents have been devised to reduce 
thrombotic risk. PARs are an important target to reduce plate-
let activation. Vorapaxar, a PAR-1 antagonist, has been tested 
in addition to dual antiplatelet therapy for prevention of throm-
botic events in patients mostly with a history of MI. Although 
Phase II trials showed a significant reduction in recurrent 
ischemic events with no increase in bleeding, Phase III 
trials showed similar reductions in ischemic events, but 
unveiled an increase in major bleeding, including intracranial 
bleeding, associated with vorapaxar. There are currently no 
ongoing trials further assessing the efficacy and safety of 
vorapaxar in the setting of MI.
Based on these findings, vorapaxar was approved for use 
only in patients at high risk of thrombosis and low risk of 
bleeding. Subsequently, the US Food and Drug Administration 
has recommended vorapaxar as an addition to dual antiplatelet 
therapy for treatment of patients with a history of MI, a low risk 
of bleeding, and no prior stroke or transient ischemic attack.47 
However, given the concerns around bleeding associated with 
the drug, its use is still restricted due to the challenges of safely 
identifying patients at high risk of thrombosis and low risk of 
bleeding who may gain the most from vorapaxar.
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